- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.08. | EQL Pharma AB: Bulletin from the annual general meeting in EQL Pharma AB on 20 August 2026 | 413 | GlobeNewswire (Europe) | Today, on 20 August 2026, the annual general meeting was held in EQL Pharma AB. A summary of the adopted resolutions follows below.
Resolution on adoption of accounts and allocation of the company's... ► Artikel lesen | |
| 12.08. | EQL PHARMA AB: Memprex© (methenamine hippurate) license signed with partner for Hungary | 3 | Cision News | ||
| 07.08. | Earnings Call: EQL Pharma signalisiert schwaches Q1 2026, setzt aber auf spätere Erholung | 2 | Investing.com Deutsch | ||
| 07.08. | Earnings Call: EQL Pharma meldet schwaches erstes Quartal, stellt aber Erholung in Aussicht | 1 | Investing.com Deutsch | ||
| 07.08. | EQL Pharma AB: Interim Report April - June 2026 | 291 | GlobeNewswire (Europe) | EQL is going through a challenging period, with supply disruptions and technically more complex products in the launch phase, which has caused delays
Comments from the CEO
The first quarter of the... ► Artikel lesen | |
| 27.07. | EQL Pharma AB: EQL Pharma recruits Oskar Karmlid as new Chief Supply Chain Officer (CSCO) | 633 | GlobeNewswire (Europe) | EQL has recruited Oskar Karmlid as its new Chief Supply Chain Officer (CSCO). Oskar will join the team in October 2026 and take over from Martin Kristofferson, who currently leads supply chain on interim... ► Artikel lesen | |
| EQL PHARMA Aktie jetzt für 0€ handeln | |||||
| 24.07. | EQL Pharma Annual Report 2025/2026 | 1 | Cision News | ||
| 17.07. | Notice of annual general meeting in EQL Pharma AB | 1 | Cision News | ||
| 15.07. | EQL PHARMA AB: Mellozzan (melatonin) approved in Kazakhstan | 1 | Cision News | ||
| 13.07. | EQL Pharma AB: Memprex© (methenamine hippurate) license signed with partner for Spain | 291 | GlobeNewswire (Europe) | EQL's key product Memprex© has now been licensed for sale in Spain with Gebro Holding GmbH (ltd), a leading local pharmaceutical company specialising in women's health, gynaecology and urology.
There... ► Artikel lesen | |
| 10.07. | Invitation to presentation in connection with EQL Pharma's interim report, first quarter, 2026/27 | 2 | Cision News | ||
| 15.06. | EQL Pharma AB: Methenamine hippurate (brand name Cystohipp©) has been launched in Germany | 315 | GlobeNewswire (Europe) | EQL's key product methenamine hippurate has now been launched in Germany by EQL's license partner Dr Pfleger under the EQL-owned brand Cystohipp©.
Cystohipp© is the only methenamine hippurate product... ► Artikel lesen | |
| 08.05. | EQL Pharma AB: Year-end Report April 2025 - March 2026 | 315 | GlobeNewswire (Europe) | During the quarter, sales rose to SEK 120.2 million, an increase of 6% from SEK 113.3 million in the previous year. Growth for next year negatively impacted by launch delays, but long-term outlook unchanged.
Comments... ► Artikel lesen | |
| 27.04. | EQL Pharma in process of recruiting new Chief Supply Chain Officer (CSCO) | 6 | Cision News | ||
| 27.03. | EQL Pharma AB: EQL Pharma CEO sells shares to finance capital gains tax from option redemption | 245 | GlobeNewswire (Europe) | EQL Pharma CEO Axel Schörling has recently sold shares for approximately SEK 1.2 million to finance capital gains tax that arose upon redemption of the option program in September 2025.
Axel Schörling... ► Artikel lesen | |
| 25.03. | EQL Pharma AB: Mellozzan (melatonin) has been approved in Italy | 205 | GlobeNewswire (Europe) | EQL's key product Mellozzan® has now received Marketing Authorization approval from the health authority in Italy (AIFA), where it will be provided to patients by EQL's licensing partner Italfarmaco... ► Artikel lesen | |
| 03.02. | EQL Pharma AB: Bulletin from the extraordinary general meeting in EQL Pharma AB on 3 February 2026 | 255 | GlobeNewswire (Europe) | Today, on 3 February 2026, the extraordinary general meeting was held in EQL Pharma AB. A summary of the adopted resolution follows below.
Resolution on implementation of a long-term incentive program... ► Artikel lesen | |
| 03.02. | EQL Pharma AB: Interim Report April - December 2025 | 264 | GlobeNewswire (Europe) | During the quarter, sales rose to SEK 118.9 million, an increase of 29% from SEK 92.2 million in the previous year. This represents a new record quarter for EQL
Comments from the CEO
The third quarter... ► Artikel lesen | |
| 04.12.25 | EQL Pharma AB: EQL Pharma recruits Anne D Jensen as new Chief Sales Officer (CSO) and Carl Lindgren leaves his position as Chief Business Development Officer (CBDO) | 436 | GlobeNewswire (Europe) | As previously announced, EQL Pharma has decided to strengthen its abilities in international commercial affairs, as a part of its European expansion. The Company has recruited Anne D. Jensen for this... ► Artikel lesen | |
| 03.12.25 | EQL Pharma AB: EQL Pharma recruits Allan Sylvest Aasberg as new Chief Financial Officer (CFO) | 235 | GlobeNewswire (Europe) | EQL Pharma strengthens and re-organizes its Finance Function to put more emphasis on business control and capital allocation. Our current CFO, Anna Jönsson, will take on the role as Head of Accounting.... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 474,35 | -0,62 % | 115 Millionen US-Dollar mit einer Zelltherapie: Warum Mesoblast, Vertex und NurExone Zellen und Exosomen unterschiedlich nutzen | ||
| UNITED THERAPEUTICS | 525,00 | +0,69 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| INDIVIOR PHARMACEUTICALS | 31,000 | -1,90 % | Indivior Pharmaceuticals Inc.: Indivior to Report Third Quarter 2026 Financial Results | ||
| CAMURUS | 59,55 | -1,57 % | Novo Nordisk legt weitere 1,3 Milliarden Dollar auf den Tisch - warum Eli Lilly und Co. schon um die nächste Milliardenplattform kämpfen | ||
| TEVA PHARMACEUTICAL INDUSTRIES | 40,180 | -0,04 % | Teva/Sanofi: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 50,13 | +0,22 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| GSK | 22,840 | 0,00 % | GSK: Lungenkrebsmittel in weltweiter Studie mit positiven Daten | DJ GSK: Lungenkrebsmittel in weltweiter Studie mit positiven Daten
Von Adria Calatayud
DOW JONES--GSK hat mit einem einlizenzierten Lungenkrebsmedikament positive Ergebnisse erzielt. Bei der... ► Artikel lesen | |
| IAMBIC THERAPEUTICS | 14,520 | -1,02 % | Biotech an der Börse: Iambic-IPO bringt 150 Millionen USD für Krebsmedikamente | Das US-Biotechunternehmen Iambic setzt bei neuen Krebsmedikamenten auf künstliche Intelligenz. Mit dem frischen Börsenkapital will es klinische Studien voranbringen und seine Forschungstechnik ausbauen.... ► Artikel lesen | |
| SCHOTT PHARMA | 25,550 | 0,00 % | SCHOTT Pharma mit PAUKENSCHLAG: Kaufen Insider bereits massiv? - Unbedingt noch vor Börsenschluss lesen! | ||
| AQUESTIVE THERAPEUTICS | 4,130 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Aquestive nach FDA-Fortschritten | ||
| BAYER | 44,070 | -0,32 % | Buy or Goodbye?: Tesla, Totalenergies, Nestle und Bayer - Die Analystenstimmen des Tages | © Foto: Ding Ting/XinHua/dpaTesla, Totalenergies, Nestle und Bayer: Die wichtigsten Analysten-Updates im Überblick Enthaltene Werte: DE000BAY0017,FR0000120271,CH0038863350,US88160R1014Den vollständigen... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 12,800 | +0,08 % | Generate Biomedicines, Inc.: Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of 'Armored' CAR T Therapy for Ovarian Cancer | Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical... ► Artikel lesen | |
| LB PHARMACEUTICALS | 39,460 | +0,10 % | Stifel reiterates Buy rating on LB Pharmaceuticals stock at $53 | ||
| KARDIGAN | 12,740 | 0,00 % | Baird stuft Kardigan mit "Outperform" ein - Kursziel 43 US-Dollar |
Das Unternehmen EQL PHARMA AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 1,736 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EQL PHARMA AB finden Sie auf Wallstreet Online.